Category Archives: Other

Innovent Initiates Ph1 INHBE China-based Study in Obesity; BioLife Receives Patent for Dissolvable Obesity Medicine; Novo’s Semaglutide Approved for MASH in China

Three cardiometabolic-related news items have been observed: Innovent Biologics initiated a Ph1 FIH study of its Q3M/Q6M SC INHBE (view CT.gov record); BioLife received a US patent for its effervescent oral peptide delivery technology (view press release); and Novo Nordisk’s injectable semaglutide received approval from NMPA for the treatment of F2-F3 MASH (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Ascletis FIH Oral Amylin Study; Moonwalk $70M Series B; New Lilly Obesity Asset; Kura Oncology Spins Out Diabetes Business; MannKind Partners for Inhaled GLP-1RA; NodThera Name Change and Topline Ph2 NLRP3i Data

A series of cardiometabolic-related news items has been observed from Ascletis Pharma, Moonwalk Biosciences, Lilly, Kura Oncology/Caspian Therapeutics, MannKind, and NodThera. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Ionis Receives PRV; Modular Medical Signs Contract with US PBM

Two cardiometabolic-related news items have been observed: Ionis Pharmaceuticals received a PRV upon approval of Zanvastro in Alexander Disease (view press release), and Modular Medical contracted with an undisclosed US PBM for its Pivot tubeless patch pump (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

G&L and Menarini Bofanglutide Licensing Agreement; G&L FIH QW Oral GLP-1RA Study; Inventiva NATiV3 LPLV Milestone; Modular Medical Patch Pump Update; Eledon Tegoprubart Updates; Superluminal Series B Financing Round

A series of cardiometabolic-related news items has been observed from Menarini, Gan & Lee Pharmaceuticals, Inventiva, Modular Medical, Eledon Pharmaceuticals, and Superluminal Medicines. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Lilly Orfor Obesity/ORC Prevention Study; NewAmsterdam Alzheimer’s Study; Novartis to Advance IL-6 Inhibitor to Ph3; Wegovy Pill Germany Launch; Pfizer Berobenatide Japan Studies; MiniMed CY Q2 ’26 Earnings; Novo Initiates AMBITION 7

A series of cardiometabolic-related news items has been observed from Lilly, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, MiniMed, and CSPC Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Ascletis Doses First Patient in Ph3; Arrowhead ESC 2026 Investor Event; Cytokinetics ACACIA-HCM Primary Results; Amgen Repatha Sub-Analyses; Alnylam Vutrisiran Sub-Analysis; Lilly 52-Week Taltz + Tirzepatide Data

A series of cardiometabolic-related news items has been observed from Ascletis Pharma, Arrowhead Pharmaceuticals, Cytokinetics, Amgen, Alnylam, and Lilly. Below, FENIX provides highlights and insights for the respective news items, including a projected approval timeline for Ph3 oral AOM development.

This content is for Read Less members only.
Already a member? Log in here

Gubra Receives Milestone Payment from AbbVie; Caliway Advances Lipolysis Drug

Two cardiometabolic-related news items have been observed: Gubra received a $50M milestone payment from AbbVie (view press release), and Caliway Biopharmaceuticals received IND clearance and IRB approval for its small molecule lipolysis drug (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here